U.S. markets closed

TransMedics Group, Inc. (TMDX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
31.78-0.24 (-0.75%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close32.02
Open32.59
Bid30.53 x 900
Ask32.00 x 1100
Day's Range26.54 - 32.73
52 Week Range10.10 - 44.12
Volume1,220,711
Avg. Volume551,655
Market Cap863.17M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateMar 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates

    TransMedics (TMDX) delivered earnings and revenue surprises of 8.00% and 24.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    TransMedics Group: Q4 Earnings Insights

    Shares of TransMedics Group (NASDAQ:TMDX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 46.51% over the past year to ($0.23), which beat the estimate of ($0.25). Revenue of $7,627,000 up by 25.92% from the same period last year, which beat the estimate of $6,040,000. Guidance TransMedics Group hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Conference Call Details Date: Mar 02, 2021 View more earnings on TMDX Time: 04:30 PM ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A//www.google.com/&eventid=2948442&sessionid=1&key=8853B71F0A0E4106745B87488A484EEA®Tag=&V2=false&sourcepage=register Technicals Company's 52-week high was at $41.20 Company's 52-week low was at $10.10 Price action over last quarter: Up 203.26% Company Profile TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes the technology to replicate near-physiologic conditions for donor organs outside of the human body. See more from BenzingaClick here for options trades from Benzinga12 Health Care Stocks Moving In Tuesday's Intraday SessionStocks That Hit 52-Week Highs On Tuesday© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.